Stockscreener 앱 받기
3.55
4.57%
-0.17
전일 마감가:
$3.72
열려 있는:
$3.73
하루 거래량:
44,360
Relative Volume:
0.53
시가총액:
$40.12M
수익:
-
순이익/손실:
$-19.09M
주가수익비율:
-1.9944
EPS:
-1.78
순현금흐름:
$-17.24M
1주 성능:
-7.07%
1개월 성능:
-11.03%
6개월 성능:
-5.96%
1년 성능:
-59.66%
1일 변동 폭
$3.50
$3.73
1주일 범위
$3.50
$4.0099
52주 변동 폭
$2.79
$9.96
Lantern Pharma Inc Stock (LTRN) Company Profile
명칭
Lantern Pharma Inc
전화
972-277-1136
주소
1920 MCKINNEY AVENUE, DALLAS, TX
LTRN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LTRN
Lantern Pharma Inc
|
3.55 | 40.12M | 0 | -19.09M | -17.24M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-10-07 | 개시 | H.C. Wainwright | Buy |
Lantern Pharma Inc 주식(LTRN)의 최신 뉴스
Lantern Pharma Inc. (NASDAQ:LTRN) Q4 2024 Earnings Call Transcript - Insider Monkey
Lantern Pharma’s Earnings Call: AI Advances Amid Financial Challenges - TipRanks
Lantern Pharma Advances AI-Driven Oncology Pipeline - TipRanks
Lantern Pharma outlines 2025 clinical milestones and key updates on oncology trials - MSN
LANTERN PHARMA Earnings Results: $LTRN Reports Quarterly Earnings - Nasdaq
Earnings call transcript: Lantern Pharma’s Q4 2024 results show increased R&D expenses - Investing.com India
Earnings call transcript: Lantern Pharma’s Q4 2024 results show increased R&D expenses By Investing.com - Investing.com South Africa
Lantern Pharma Inc Qtrly EPS $-0.54 - Marketscreener.com
Lantern Pharma Inc (LTRN) Reports Q4 EPS of -$0.51, Aligning wit - GuruFocus.com
Lantern Pharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Lantern Pharma Reports Q4 2024 Financial Results and AI Progress - TipRanks
Lantern Pharma Reports 86% Clinical Benefit Rate in Cancer Trial, Q4 Results | LTRN Stock News - StockTitan
Preview: Lantern Pharma's Earnings - Benzinga
Lantern Pharma Inc expected to post a loss of 51 cents a shareEarnings Preview - TradingView
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2024 Operating & Financial Results on March 27th, 2025 at 4:30 p.m. ET - BioSpace
Lantern Pharma's AI Platform Breakthrough: Q4 Results and Clinical Trial Milestones Revealed - StockTitan
LTRN: M&A Illuminates GBM Value - Yahoo Finance
Critical Analysis: Dyne Therapeutics (NASDAQ:DYN) and Lantern Pharma (NASDAQ:LTRN) - Defense World
Lantern Pharma (LTRN) Expected to Announce Earnings on Monday - Defense World
Sanctuary Advisors LLC Purchases New Holdings in Lantern Pharma Inc. (NASDAQ:LTRN) - Defense World
Lantern Pharma (LTRN) Files Patent for AI-Powered Blood-Brain Barrier Prediction Tech - Insider Monkey
Lantern Pharma advances AI-driven drug development with patent - Investing.com India
Lantern Pharma advances AI-driven drug development with patent By Investing.com - Investing.com Nigeria
Lantern Pharma Announces PCT Patent Application Publication for Innovative, High Performing, Machine Learning Model for Predicting Blood Brain Barrier Permeability of Drug-Candidates - Business Wire
Perigon Wealth Management LLC Decreases Stake in Lantern Pharma Inc. (NASDAQ:LTRN) - Defense World
Lantern Pharma (NASDAQ:LTRN) Stock Price Down 15% – Here’s What Happened - Defense World
Lantern Pharma Inc. (LTRN) Enhances RADR® AI Platform to Accelerate Development of Antibody-Drug Conjugates (ADCs) for Targeted Cancer Therapies - Yahoo Finance
Top 10 AI Stocks Dominating Wall Street - Insider Monkey
Lantern Pharma Unveils Innovative AI-Powered Module to Improve the Precision, Cost and Timelines of Antibody-Drug Conjugate (ADC) Development for Cancer - BioSpace
Lantern Pharma Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R) - ACCESS Newswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Lantern Pharma Inc. (LTRN): AI-Driven Cancer Drug Development - Insider Monkey
Lantern Pharma Extends CSO’s Employment Agreement - TipRanks
Lantern Pharma (NASDAQ:LTRN) Stock Price Up 13.3% – What’s Next? - Defense World
Oncology Drugs Fast-Tracked by the FDA in December 2024 - Oncology News Central
Is Lantern Pharma (NASDAQ:LTRN) In A Good Position To Invest In Growth? - Yahoo Finance
AI-Powered Cancer Solutions: Lantern Pharma (LTRN) Launches Phase 2 Trial in Taiwan - Insider Monkey
Lantern Pharma starts dosing in Taiwan in non-smoker lung cancer trial - Yahoo Finance
Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients - Business Wire
Lantern Pharma Inc. (LTRN) Receives Second FDA Fast Track Designation for LP-184 in Triple Negative Breast Cancer - Yahoo Finance
15 AI News Updates That Broke The Internet - Insider Monkey
LTRNLantern Pharma Inc. Latest Stock News & Market Updates - StockTitan
Lantern Pharma Shares Rise After Fast-Track Designation for Cancer Treatment - Marketscreener.com
LP-184 gains FDA fast track for triple negative breast cancer - Investing.com
Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC) - Eagle-Tribune
Lantern Pharma's LP-184 Shows 6x Better GBM Treatment Efficacy in Latest Trial Data | LTRN Stock News - StockTitan
Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality - BioSpace
Lantern Pharma Inc (LTRN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Lantern Pharma Inc 주식 (LTRN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Fletcher Aaron G.L. | 10% Owner |
May 23 '24 |
Sale |
6.25 |
10,000 |
62,500 |
59,326 |
0.39%
0.34%
자본화:
|
볼륨(24시간):